Table 5.
Follow-up analysis of monocyte subsets and functional molecules (24-months of suppressive cART).
| LR-Subjects (6) | HR-Subjects (5) | ||||||
|---|---|---|---|---|---|---|---|
| Before cART | Post cART | pW | Before cART | Post cART | pW | pM-W | |
| % Classical monocytes | 85.3 [74.5–91.8] | 81.1 [60.0–91.8] | 0.3 | 78.8 [69.0–85.4] | 80.1 [72.2–87.5] | 0.5 | 0.9 |
| MFI CD11b | 2,285 [2,154–2,806] | 2298 [2,028–2,785] | 0.5 | 2,399 [1,371–2,883] | 1,797 [1,142–1,977] | 0.08 | 0.022 |
| % CCR2 | 82.7 [66.6–92.7] | 93.4 [86.3–97.5] | 0.046 | 81.4 [78.9–84.9] | 93.1 [90.8–95.1] | 0.043 | 0.7 |
| % β7 | 18.3 [4.3–32.2] | 13.8 [4.2–25.4] | 0.6 | 4.8 [2.1–52.1] | 9.4 [1.8–37.1] | 0.5 | 0.9 |
| % IDO | 1.0 [0.7–4.1] | 0.2 [0.1–1.4] | 0.028 | 1.0 [0.9–7.2] | 0.4 [0.1–6.3] | 0.08 | 0.8 |
| % PDL1 | 26.5 [12.8–47.3] | 16.1 [5.9–54.2] | 0.5 | 13.7 [4.1–47.0] | 5.3 [2.8–22.4] | 0.08 | 0.2 |
| % Intermediate monocytes | 8.8 [4.1–13.3] | 7.0 [1.7–19.9] | 0.9 | 11.5 [6.0–19.9] | 5.1 [3.5–13.6] | 0.08 | 0.9 |
| MFI CD16 | 1,441 [700–1,677] | 1,298 [730–1,653] | 0.8 | 536 [462–1,007] | 1,043 [504–1,227] | 0.043 | 0.2 |
| MFI CD11b | 2,792 [2,369–3,178] | 3,112 [2,475–4,311] | 0.3 | 2,836 [2,031–3,019] | 2,031 [1,484–2,570] | 0.138 | 0.068 |
| % CCR2 | 53.9 [41.6–75.2] | 63.2 [61.2–75.4] | 0.2 | 57.9 [44.7–64.8] | 60.3 [51.4–86.4] | 0.3 | 0.4 |
| % β7 | 13.2 [2.8–19.8] | 7.3 [2.7–19.7] | 0.5 | 6.7 [1.9–41.1] | 3.4 [1.5–18.0] | 0.3 | 0.6 |
| % IDO | 3.6 [2.0–9.7] | 0.5 [0.3–3.3] | 0.028 | 1.9 [1.6–11.8] | 0.7 [0.0–9.1] | 0.138 | 0.9 |
| % PDL1 | 46.3 [39.0–62.9] | 38.3 [24.0–68.1] | 0.2 | 24.5 [22.3–81.5] | 17.9 [9.6–37.2] | 0.138 | 0.2 |
| % Patrolling monocytes | 2.8 [0.8–8.2] | 7.0 [1.6–15.8] | 0.2 | 2.4 [1.2–9.0] | 7.7 [2.4–10.0] | 0.5 | 0.9 |
| MFI CD16 | 2,926 [,2037–4,878] | 3,122 [,2842–3,531] | 0.9 | 1,677 [1,160–4,545] | 2,128 [1,630–3,170] | 0.9 | 0.068 |
| MFI CD11b | 980 [708–1,256] | 803 [635–1,026] | 0.6 | 795 [520–972] | 582 [484–682] | 0.08 | 0.068 |
| % CCR2 | 9.6 [5.3–31.5] | 12.7 [6.5–20.2] | 0.6 | 20.6 [7.5–22.4] | 8.3 [4.1–20.6] | 0.7 | 0.7 |
| % β7 | 6.9 [4.8–17.0] | 4.7 [4.2–8.1] | 0.075 | 6.9 [6.0–38.6] | 5.5 [4.2–17.2] | 0.7 | 0.5 |
| % IDO | 0.5 [0.3–1.7] | 0.2 [0.1–0.6] | 0.046 | 0.4 [0.3–2.7] | 0.4 [0.2–1.5] | 0.2 | 0.5 |
| % PDL1 | 74.1 [61.8–86.2] | 42.6 [28.7–57.0] | 0.046 | 47.4 [29.2–65.8] | 18.3 [10.7–35.9] | 0.043 | 0.068 |
| % Shedding monocytes | 3.5 [1.3–5.3] | 5.0 [4.2–5.7] | 0.028 | 4.8 [3.8–7.1] | 5.1 [4.3–7.6] | 0.5 | 0.8 |
Variables are expressed as median and interquartile range [IQR]. pW, Wilcoxon rank test was used to analyze longitudinal comparisons. pM-W, Mann–Whitney U test was used for transversal comparisons of post cART data.
Statistically significant values are highlighted in bold, p < 0.005.